Equities Analysts Set Expectations for MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2025 EPS estimates for Mirum Pharmaceuticals in a research note issued on Thursday, May 8th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($1.13) per share for the year, up from their previous forecast of ($1.40). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share.

Several other analysts also recently commented on MIRM. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday, February 28th. JMP Securities increased their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research report on Friday. Raymond James increased their price target on shares of Mirum Pharmaceuticals from $73.00 to $77.00 and gave the company a "strong-buy" rating in a research report on Tuesday. Finally, Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $60.64.

Mirum Pharmaceuticals Stock Down 0.7%

Shares of MIRM stock traded down $0.30 on Monday, hitting $45.27. The stock had a trading volume of 422,516 shares, compared to its average volume of 525,600. The business has a 50 day moving average of $42.84 and a 200 day moving average of $44.34. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -22.41 and a beta of 0.95. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a 12-month low of $23.83 and a 12-month high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm's revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.54) earnings per share.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 7,879 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the transaction, the chief operating officer now owns 18,672 shares in the company, valued at $825,489.12. This trade represents a 29.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 57,606 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This represents a 92.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,764 shares of company stock worth $4,109,161 over the last quarter. 14.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of large investors have recently modified their holdings of MIRM. CWM LLC boosted its position in shares of Mirum Pharmaceuticals by 259.4% in the first quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after acquiring an additional 428 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $35,000. GF Fund Management CO. LTD. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $42,000. Finally, R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $69,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.